Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
GYRE THERAPEUTICS, INC. completed a disposition involving GC Biopharma Corp. for $6 million in cash (closed 2023-02-27).
- Action
- disposition
- Counterparty
- GC Biopharma Corp.
- Consideration
- $6 million in cash
- Closing
- 2023-02-27
Exact text from the filing
(MarzAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”). In consideration for the purchase of the Purchased Assets, Buyer will pay Catalyst a total of $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back until twenty-four months after the closing, subject to the satisfaction of post-closing
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GYRE THERAPEUTICS, INC. entered into Purchase Agreement with GC Biopharma Corp. valued at $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back (effective 2023-02-27).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- GC Biopharma Corp.
- Value
- $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back
- Effective
- 2023-02-27
Exact text from the filing
On February 27, 2023, Catalyst Biosciences, Inc. (“Catalyst”) entered into and closed on an Asset Purchase Agreement (the “Purchase Agreement”) with GC Biopharma Corp. (“Buyer”), pursuant to which Buyer acquired on such date Catalyst’s legacy rare bleeding disorder program, including marzeptacog alpha activated (MarZAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”).
View on SEC.gov